outreach oct 2010

7/31/2019 Outreach Oct 2010

1/16

October 2010OUTREACH

1

OUTREACHVOl X issUE iii OCTObER 2010

Record numer of advocate

ray on Capto H forPancreatc CancerAdvocacy Day 2010


2/16

Dear Pancreatic Cancer Action Network Friends:

Thanks to the inspiring generosity of our stellar donors

and support of volunteers nationwide, our 2009-10 scal

year, that ended on June 30, was another successful one

for the organization. I want to personally acknowledge

everyone who contributed for their benevolence in helping

to further the organizations mission.

These donations helped to fund one of the important aims of the Pancreatic Cancer

Action Network: our research grants program. In 2010, approximately $2.3 million

was incurred to fund research grants awarded to outstanding investigators. To

learn more about our 2011 research grants program, please see page 1.

In other news, the endorsement of a respected celebrity is helping to further

raise the organizations prole. Writer, director and best-selling author Lisa Niemi

Swayze, who lost her husband, Patrick Swayze, to pancreatic cancer in 2009, has

agreed to serve as our spokesperson. We are extremely grateful for her support

and dedication.

You may have received a heartfelt e-mail from Lisa on September 14, the

rst anniversary of Patricks death, urging you to be a hero in the ght against

pancreatic cancer. Lisa kicked off our November awareness campaign with a

special message about the urgent need to ght the disease and with a touching

video promoting our theme: Be a Hero in the Fight Against Pancreatic Cancer.

Know It. Fight It. End It. (Watch Lisa's video at www.knowitnditendit.org.) We are

excited that Lisa is lending her voice to our cause and this campaign. To nd out

how you can take action this November as part of the campaign, turn to page 6.

As always, your ongoing support and generosity, enabling us to continue providing

much-needed, high-quality services and programs for the pancreatic cancer

community, is deeply appreciated.

Sincerely,

Jason Kuhn

Board Chair

P.S. Congratulations to David Tuveson, MD, PhD, who began serving a two-year

term as the chair of the organization's Scientic Advisory Board in July. Look for

more information about Dr. Tuveson's appointment in the February 2011 issue of

Outreach.

BOARD OF DIRECTORSJason Kuhn, Chair, Tampa, Fla.

Stephanie R. Davis, JD, MA, Secretary,

Sherman Oaks, Calif.

Tim Ennis, Boca Raton, Fla.

Julie Fleshman, JD, MBA, President & CEO

Los Angeles

Stevan Holmberg, MBA, DBA, Potomac, M

Peter Kovler, Washington, D.C.

Laurie MacCaskill, Los Angeles

Jai Pausch, Hampton Roads, Va.

Stuart Rickerson, Rancho Santa Fe, Calif.

Cynthia Stroum, Founding Chair Emeritus,

Seattle

SCIENTIFIC ADVISORY BOARDDavid Tuveson, MD, PhD, Chair,

Cambridge Research Institute/CRUK

Dafna Bar-Sagi, PhD, New York University

Teri Brentnall, MD, University of WashingtoMichael Hollingsworth, PhD,

University of Nebraska Medical Center

Ralph Hruban, MD, Johns Hopkins Univers

Elizabeth Jaffee, MD, Johns Hopkins Unive

Craig Logsdon, PhD,

MD Anderson Cancer Center

Margaret Mandelson, PhD,

Fred Hutchinson Cancer Research Cent

Gloria Petersen, PhD, Mayo Clinic

Margaret Tempero, MD,

University of California, San Francisco

Selwyn Vickers, MD, University of Minneso

Geoffrey Wahl, PhD, Salk Institute

MEDICAL ADVISORY COUNCILMark Talamonti, MD, Chair,

NorthShore University HealthSystem

Jordan Berlin, MD,

Vanderbilt-Ingram Cancer Center

Marcia Canto, MD, Johns Hopkins Univers

Christopher Crane, MD,


Jason Fleming, MD,


Julie Meddles, RD, LD,

Ohio State University Medical Center

Mary Mulcahy, MD,

Northwestern University

Maria Petzel, RD, CSO, LD, CNSD,


Vincent Picozzi, MD,

Virginia Mason Medical Center

Mark Pochapin, MD, Jay Monahan Center

Gastrointestinal Health

CHAIRS MESSAGECELEBRATING ANOTHER SUCCESSFUL YEAR

OUR MISSIONThe Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together

to advance research, support patients and create hope for those affected by pancreatic cancer.Cover image: Angela Johnson

www.redboatimages.com


3/16

October 2010 OUTREACH 1

The Pancreatic Cancer Action Network has committed al-

most $3 million to research through its 2011 grants program,representing a 30 percent increase compared to 2010 funding.

Since the inception of its grants program in 2003, the

organization has awarded 56 grants totaling more than

$7.2 million to scientists across the country.

As the 2010 grant recipients embark on their proposed

research projects, another group of highly talented scientists

and clinicians will soon be welcomed into the organizations

research family. The grants program addresses two major

barriers to research progress in pancreatic cancer a sparse

research community and limited funding by attracting and

retaining bright investigators to study pancreatic cancer, and

supporting their research endeavors to accelerate scienticbreakthroughs.

In addition to providing funding for research projects, the

Pancreatic Cancer Action Network also strives to mold future

leaders in the eld. Three of the research grant mechanisms

are specically designed to support promising scientists

early in their careers: Fellowship, Career Development, and

Pathway to Leadership awards. Attracting young research-

ers to pursue careers focused on pancreatic cancer is an

ongoing goal of the organization. To accomplish this, mentor

relationships are fostered between young researchers and

more senior scientists, based on common research interests.

Further, grant recipients are given multiple opportunities

to interact and present their work to members of the

organizations Scientic Advisory Board and Medical

Advisory Council, gaining invaluable insights, advice and the

potential for future collaborations.

The nal grant mechanism is the Innovative Grant, for-

merly known as the Pilot Grant. Innovative Grants support

projects that are novel, pose questions that have not yet

been addressed, or utilize unconventional experimental ap-

proaches. Independent investigators at any stage of their

careers are eligible for Innovative Grants. This mechanism

also invites cancer researchers focused on other tumor typesto apply their knowledge and expertise to pancreatic cancer,

further strengthening and expanding the pancreatic cancer

research community. (Note: By press time, the deadline for

Letters of Intent for the Innovative Grant had passed.)

The 2011 Pancreatic Cancer Action Network grants will

once again be administered in partnership with the American

Association for Cancer Research (AACR). AACRs involve-

ment ensures unbiased funding of the most meritorious

research projects, via a rigorous peer-review system, empha-

sizing originality and scientic credibility.

Grant applications must be submitted online through

proposalCENTRAL (https://proposalcentral.altum.com). Thegrant terms start July 1, 2011.

For additional information, visit http://www.pancan.org/grants

or contact Rhonda Aizenberg, PhD, at [email protected].

To learn more about opportunities to provide nancial support

for our research program, contact Pamela Acosta Marquardt at

[email protected].

NEARLY $3 MILLION COMMITTED TO RESEARCH FOR 2011APPLICATION DEADLINE IS OCTOBER 27 FOR MOST GRANTS

2011 GRANTS PROGRAM FUNDING OPPORTUNITIES

Pathway to Leadership Grant

Up to ve years of support totaling $600,000 for a

highly promising early career scientist beginning in a

postdoctoral position and continuing through transition

to independence.

Eligibility: Applicant must be in the rst ve years of a

postdoctoral or clinical research fellowship (i.e., started

a fellowship on or after July 2, 2006) at the beginning of

the grant term.

Application Deadline: October 27, 2010, Noon ET

Fellowship Award

One-year grant totaling $45,000 for an early career

scientist to support his/her mentored research.

Eligibility: Applicant must be in the rst three years of a

postdoctoral or clinical research fellowship (i.e., started

fellowship on or after July 2, 2008) at the beginning of

the grant term.


Career Development Award

Two-year grant totaling $200,000 for a newly indepen-

dent investigator to develop or strengthen a research

program in pancreatic cancer.

Eligibility:Applicant must be in the rst four years of a

faculty appointment (i.e., completed postdoctoral/clini-

cal fellowship on or after July 2, 2007) at the beginning

of the grant term.


Innovative Grant

Two-year grant totaling $200,000 intended to further

the development of new and innovative ideas and

approaches, including those successful in other areas of

cancer that show promise for pancreatic cancer.

Eligibility: Applicant must be an independent junior or

senior investigator (not including postdoctoral/clinical

fellows).

Letter of Intent Deadline: Closed


4/16

2 October 2010 OUTREACH

Dr. McCormick received the2010 Fredman Family Founda-

tion Pancreatic Cancer Action

Network AACR Innovative

Grant. The author of several of

the most widely cited papers in

cancer biology, Dr. McCormick

has revolutionized understand-

ing of cancer-causing viruses

and identied important regu-

lators of a signaling pathway

altered in many cancer types,

including pancreatic cancer. He founded Onyx Pharmaceu-ticals in 1992, where he developed a drug commonly used to

treat certain kidney and liver cancers. When the University

of California, San Francisco Helen Diller Family Comprehen-

sive Cancer Center was founded in 1998, Dr. McCormick was

recruited to serve as its director, a position he still holds.

While several of the Pancreatic Cancer Action Network

grant mechanisms cater to young scientists early in their

careers, the Innovative Grant is open to independent inves-

tigators at any career level. The purpose of this award is

to support creative ideas and unconventional experimental

approaches. This funding opportunity welcomes projects

proposed by more senior investigators for whom pancreatic

cancer has not previously been a primary research focus.

The knowledge and experience provided by these scientists

can greatly enhance progress in pancreatic cancer research.

The Innovative Grant is a perfect t for Dr. McCormick.

A great deal of his work has focused on a cell signaling

pathway involving a protein called Ras. This protein plays

a critical role in signaling that ultimately results in growth,

survival, movement, and other cellular properties that, whenaltered, are traits of cancer cells. Dr. McCormick con-

tributed greatly to the understanding of this pathway by

discovering and characterizing additional proteins that are

involved in positively and negatively regulating the activated

state of Ras. Mutations of Ras and alterations of Ras path-

way members are extremely common in cancer, especially

pancreatic.

In fact, the specic Ras family protein called K-Ras has

been shown to be mutated in up to 90 percent of pancre-

atic tumors. It is well established that K-Ras plays a crucial

role in the initiation and maintenance of pancreatic cancer.

Because of cancer cells dependence on K-Ras signaling,the protein makes an attractive candidate as a therapeutic

target. However, previous attempts at targeting K-Ras in

pancreatic and other cancers have been unsuccessful.

For his funded project, Dr. McCormick proposes devel-

oping a drug to block K-Ras in an unconventional manner.

Investigators know that the K-Ras protein must be embedded

in the cell membrane in order to become active. Rather than

attempt to block the protein activity directly, McCormick aims

to create a drug that will bind to K-Ras and physically impede

its attachment to the cell membrane. McCormick calls his

strategy a new attack on an old target.

When asked what advice he would give to early-career

scientists focused on pancreatic cancer, McCormick shared

a simple message: Now is the time. We have the best knowl-

edge, best tools at our disposal to try to make an impact.

K-Ras has proven to be an elusive target to other cancer

researchers. Previously, Dr. McCormick focused his atten-

tion on observing and understanding Ras and its signaling

partners. He is now motivated to nd a novel way to block

K-Ras activity as a means to treat pancreatic cancer.

MEET A GRANTEEFRANK MCCORMICK, PHD, FRS: LAUNCHING A NEW ATTACK ON K-RAS

Frank McCormick, PhD, FRS

Fredman family

Last year, our family funded our rst research grant through thePancreatic Cancer Action Network after losing our beautiful mother topancreatic cancer. We found comfort in supporting the work of thismost worthy organization while at the same time paying tribute to herThis year, we are thrilled to be able to fund an even larger grant tosupport the innovative thinking that we feel is necessary to one daynd a cure. Our family is honored to play a role in helping to shapewhat is needed to stop this insidious disease.

Fredman Family Foundation (in honor of Ruth Fredman Cernea)


5/16


As one of the countrys leading cancer killers, pancreatic

cancer presents a signicant challenge for scientists andclinicians to understand, diagnose, and treat. While great

strides have been made in ghting other forms of cancer in

recent years, breakthroughs in pancreatic cancer have elud-

ed investigators.

Pancreatic cancer research has lagged behind that of

other cancer types for multiple reasons. First, people do not

generally pay much attention to the pancreas. The same

goes for doctors, who do not have the means to routinely

check their patients pancreatic health. If present, symptoms

of pancreatic cancer are often quite nonspecic, leading to

tragic delays in diagnosis.

Because of the location and diverse functions of the

organ, and a lack of obvious symptoms, the majority of pan-

creatic tumors are diagnosed late, when surgery is no longer

a feasible option. Surgery is the most effective way to treat

pancreatic cancer, but the majority of patients are not viable

candidates. Although numerous combinations of chemo-

therapeutics, targeted drugs, and radiation have been tested

to treat pancreatic cancer, few benecial treatment options

currently exist.

Improved diagnostic tools and therapies have revolu-

tionized the management of other cancer types. Bright and

hard-working doctors and scientists worldwide tirelessly

strive to bring the same successes to pancreatic cancer.

However, none of these advances will be possible without

adequate funding and other needed resources.

The vast majority of biomedical research conducted in the

United States is funded by the government, via the NationalInstitutes of Health (NIH). Within the NIH, the National Cancer

Institute (NCI) supports research on cancer.

In 2009, the NCI dedicated a mere two percent of its total

budget to research grants focused on pancreatic cancer. For

decades, pancreatic cancer has received a similar fraction

of NCI dollars, representing dramatically less funding than its

societal health toll demands. The funding awarded to other

cancer types, such as breast and prostate, eclipses that allot-

ted to pancreatic cancer. Consequently, the diseases which

receive the larger amounts of funding generally see greater re-

search advancements and subsequent clinical improvements.

The successes seen in breast, prostate, and other cancer

types serve as evidence that the appropriate combination of

bright minds, hard work, and ample research funds can and

will lead to similar advances in pancreatic cancer diagnosis

and treatment.

Through its grants program, the Pancreatic Cancer Action

Network is dedicated to attracting and retaining bright scien-

tists to study pancreatic cancer. (See page 1.) Additionally,

the organization encourages increased federal research fund-

ing by meeting directly with the NCI staff, educating Members

of Congress and promoting legislation urging the NCI to create

a strategic plan and targeted research program to address

pancreatic cancer. The combination of these efforts with en-

hanced cooperation from the NCI will be necessary to make

pancreatic cancer progress a reality.

INCREASED FEDERAL FUNDING URGENTLYNEEDED FOR PANCREATIC CANCER RESEARCH

Stand Up To Cancer (SU2C), a charitable

initiative of the Entertainment Industry

Foundation, was formed in 2008 to support

groundbreaking research aimed at delivering new cancer

treatments to patients in an accelerated timeframe.

In 2009, SU2C awarded an unprecedented $18 million

grant to fund a scientic dream team focused on studying pan-

creatic cancer. The pancreatic cancer dream team comprises

scientists from notable institutions across the U.S. and is led

by Daniel Von Hoff, MD, Director of the Clinical Translational

Research Division at the Translational Genomics Research

Institute (TGen), and Craig Thompson, MD, Director of the

Abramson Cancer Center at the University of Pennsylvania.

The researchers on this team are working to better

understand how pancreatic tumors utilize glucose and/

or glutamine as fuel. Meanwhile, members of the team

at Johns Hopkins University (Drs. Dan Laheru and Ana

De Jesus) recently opened a Phase II clinical trial to test

the effectiveness of a new targeted agent in patients with

metastatic pancreatic cancer.

The Phase II trial involves a new drug targeting the

hedgehog pathway, called GDC-0449, used in combination

with gemcitabine (Gemzar) and nab-paclitaxel (Abraxane).

Scientists have demonstrated that the hedgehog pathway

plays a role in maintaining a dense layer around the tumor,

which is thought to prevent drug delivery to it.

To learn more about this clinical trial or other pancreatic

cancer treatment options, contact the Pancreatic Cancer

Action Network's PALS program toll-free at 877-272-6226, M-F

7am-5pm Pacic Time or e-mail [email protected].

SU2C DREAM TEAM OPENS CLINICAL TRIAL


6/16


Nearly 1,000 Pancreatic Cancer Action Network supporters

from across the nation joined forces to support the fourth

annual Pancreatic Cancer Advocacy Day and the National

Call-In in June.

On June 21, more than 400 advocates gathered in

Washington, D.C. and were trained on up-to-the-minute

advocacy messaging,

C o n g r e s s i o n a l

s t r a t e g y , a n d

powerful ways of

strengthening the

impact of advocacy

efforts in their owncommunit ies. The

fol lowing day, the

supporters traveled

to Capitol Hill to share

t h e i r s t o r i e s a n d

ask their Senators

and Representatives

to co-sponsor the

Pancreatic Cancer

Research & Education

Ac t (S . 3220 /H .R .

745), a bill thatwill ensure that the

National Cancer

Institute (NCI) creates a strategic plan to make progress in

pancreatic cancer research.

During the National Call-In on June 22,

more than 2,000 calls were placed to

more than 340 Congressional ofces,

echoing similar requests that were put

forth during the in-person meetings with

legislators in Washington, D.C. The

combined efforts resulted in securing

the support of more than half of the U.S.

House of Representatives and one-fth of

the U.S. Senate for the bill. The efforts

also enabled us to begin an impressive

push forward to call for Congress to bring

the bill to a vote.

Now that we have secured signicant

bi-partisan support for the Pancreatic

Cancer Research & Education Act, it is even more important

that we continue our efforts, said Megan Gordon Don,

Director of Government Affairs & Advocacy. First, we need

you to ask your U.S. Representative to do everything that they

can to bring H.R. 745 to a vote and to get it passed before

they return home this year. If the bill doesnt pass before the

House adjourns, though, well need to work together to get

all of our co-sponsors back on board, as well as many new

ones when they return in January 2011.

Well keep you posted on the latest developments at

www.pancan.org/TakeAction, she added. Well need your

help either way. This is truly an exciting time to be involvedin advocacy. When the bill passes, not only will it mean

critical pancreatic cancer research funding and essential

accountability at the NCI, but we will be able to celebrate

having made history together.

FOURTH ANNUAL PANCREATIC CANCER ADVOCACY DAY ANDNATIONAL CALL-IN HAILED AS NOTABLE SUCCESS

Pancreatic Cancer Advocacy Day participants who met with Rep. Bill Foster (D-IL), third from left,

included, from left, Medical Advisory Council Chair Mark Talamonti, MD, survivor Judy Sarvas, Claudia

Trapp, Brittney Talamonti, Jason Talamonti and Anne Talamonti.

Capitol Hill was awash in purple on June22, when more than 400 advocates carried

bags with advocacy messaging.

The Pancreatic Cancer Research & Education Act

(S. 3320/H.R.745)

U.S. Senators co-sponsoring*:

26%(26/100 Senators)U.S. Representatives co-sponsoring*:

56.3%(245/435 Reps.)*As of Sept. 30, 2010


7/16


SAVE THE DATEPancreatic Cancer Advocacy Day 2011June 13 and 14 Washington, D.C.Registration opens during Winter 2011.

To learn more, visit www.pancan.org/AdvocacyDay

Twin Cities Afliate advocate and PurpleRide Minneapolis Co-founder Renita

Van Dusen gestures as she boards a bus bound for Capitol Hill.

Pancreatic Cancer Action Network Board Member Jai Pausch prepares her

son, Dylan, before he speaks as his brother, Logan, looks on at Advocacy

Day training.

Boston Advocacy Coordinator Yadhav Jayaraman and his family appeared

at several Congressional meetings during Advocacy Day.

From left, advocate Fred Brindisi, Pancreatic Cancer Action Network Board

Member and survivor Stuart Rickerson, and advocate Silvana Brindisi strat-

egize for their meetings with their Members of Congress.

Boise Afliate Coordinator and survivor John Bradley advocated with his

sons Ian and Rae at the event.

Senate Majority Leader Senator Harry Reid (D-NV), second from left, met

with advocates, from left, Lisa Hamburg, survivor Stuart Jed, Shannon

Wood, Pancreatic Cancer Action Network President and CEO Julie Flesh-

man and Ginnie Jed.


8/16


BE A HERO THIS FALLOn September 14, the Pancreatic Cancer Action Network

launched its annual fall campaign designed to raise

awareness, increase advocacy and grow the community of

supporters committed to nding a cure for pancreatic cancer.

As with the 2009 campaign, an interactive, user-friendly site

was created that not only engages visitors, but gives them the

tools they need to become effective advocates for the cause.

The campaign precedes Pancreatic Cancer Awareness

Month in November.

This years theme is Be a Hero in the Fight Against

Pancreatic Cancer: Know It. Fight It. End It. The campaign

will focus on two areas: 1.) engaging supporters to explain

why they or their loved ones

are heroes in the ght and 2.)

activating the organizations

base of supporters to take one

simple action every day be-tween the launch of the Hero

campaign on September 14

and November 30 to heighten

awareness of the disease.

We want to show peo-

ple that not only can anyone

be a hero in the ght against

pancreatic cancer, but that to-

gether we are an even stronger

force that can make a real dif-

ference, said Lisa Gilmour,

Director of Marketing and Com-munications. On the homepage of our Hero website, well

feature ve personal videos, which started with the launch

of a touching message from Lisa Niemi Swayze on Septem-

ber 14, the rst anniversary of the passing of her husband,

Patrick Swayze. We are thrilled that Lisa has agreed to sup-

port the Pancreatic Cancer Action Network to honor Patricks

memory and to help further our mission by bringing more at-

tention to the disease.

Other supporters can also help spread the word by visiting

the organizations new Hero website at

www.knowitghtitendit.org to nd simple yet highly impact-

ful actions anyone can take to help make a difference. These

include sending a letter to your elected ofcials, wearing pur-

ple to work, mailing a letter to the editor of your local paper,

or forwarding the many compelling and personal hero stories

on our website to friends and family to help spread the word

about the need for more aware-

ness, Lisa Gilmour added.

An interactive, download-

able action calendar featuring

suggestions for daily activitiesis also available on the site. The

calendar offers advocates, vol-

unteers and supporters a wide

variety of ways to take action,

with a strong focus on advocacy

actions to reach out to elected

ofcials about the need to co-

sponsor the Pancreatic Cancer

Research & Education Act.

In addition to the calendar,

patient and supporter stories

will be featured throughout thesite, along with additional information and resources about

other ways to become an advocate for the cure.

Do your part today and encourage everyone you know to

visit www.knowitghtitendit.org .

LISA NIEMI SWAYZE TO SERVE AS ORGANIZATION SPOKESPERSO

Writer, director and best-selling author Lisa Niemi Swayze will serve as a spokesperson for the Pancreatic CanAction Network to build awareness of the disease that took the life of her husband, Patrick Swayze, in 2009.

In addition to helping launch the organizations annual fall campaign that precedes Pancreatic Cancer AwarenMonth in November, Lisa will be presented with the Pancreatic Cancer Action Network's Spirit of Hope Award at 13th annual An Evening with the Stars gala on October 30. She will also appear in public service announcemeand serve as a guest speaker at various events for the organization.

I joined forces with the Pancreatic Cancer Action Network in honor of Patrick, because I know it would meanlot to him if his illness made a difference in the lives of others, Lisa said. My involvement is the best way I knof to make progress in ghting this terrible disease.

Along with Patrick, Lisa co-wrote his memoir entitled "The Time of My Life," which provides a behind-the-scenes look at their successHollywood and their remarkable love story. The book was a New York Times" Best Seller, debuting at number four on the newspaper's las well as an international best seller.

Lisa currently divides her time between Los Angeles and her ranch in New Mexico.


9/16


The Patient and Liaison Services (PALS) program of the

Pancreatic Cancer Action Network is pleased to announce

the launch of an innovative outreach effort called the Patient

Navigation Outreach Program. The endeavor is intended

to improve certain patterns of pancreatic cancer diagnosis

and treatment and ensure that pancreatic cancer patients

and their caregivers are made aware of the resources and

information available through the PALS program.

Healthcare professionals not only play a critical role in

the diagnosis and care of pancreatic cancer patients but are

also uniquely positioned to refer them and their caregivers

to useful resources and support services. Therefore, the

program will focus on equipping the healthcare community

with the information, tools and resources they can use to

effectively meet the needs of pancreatic cancer patients and

their caregivers.Pancreatic cancer is very difcult to diagnose, with no

established screening or early detection tools. Diagnosis is

often made in the late stages of the disease. The rst goal

of the program is to encourage healthcare professionals to

appropriately consider pancreatic cancer when diagnosing a

patient with specic symptoms. By encouraging physicians

to keep pancreatic cancer in mind and to consider the disease

as a possible diagnosis when examining their patients, we

hope to shorten the length of time between an initial doctors

visit and an eventual diagnosis of pancreatic cancer, said

Anitra Talley, Director of the PALS program.

The second goal of the program is to encouragephysicians who are diagnosing pancreatic cancer patients

to refer them to a surgeon who treats a high volume of

pancreatic cancer patients, to an oncologist who focuses

on gastrointestinal or pancreatic cancer, or to an institution

conducting clinical trials for pancreatic cancer. This approach

will ensure that such patients are made aware of treatment

options available to them and are able to make informed

decisions about their care.

Lastly, the third goal of the Patient Navigation Outreach

Program is to continue to raise awareness about the PALS

program among healthcare professionals so more patients

facing the disease have access to its services.

Through a cost-free information line, the PALS

program provides personalized, up-to-date information

about the disease, clinical trials, treatment options, diet

and nutrition, side

effect and symptom

management and

support resources.

The PALS program

educates pancreatic

cancer patients andtheir caregivers about

many aspects of the

disease and connects them with needed resources so that

they are well-equipped and empowered to make informed

decisions about care and treatment.

To deliver the messages aligned with the program

to a broad audience of healthcare professionals, PALS will

use a variety of tactics to heighten awareness, Tally added.

These outreach methods will include a far-reaching media

campaign, new educational materials, in-person outreach

at medical meetings and conferences, targeted mailings

and community-level outreach performed by volunteers incommunities nationwide.

For more information about the Patient Navigation

Outreach Program or to contact a PALS Associate for

information about pancreatic cancer, call PALS toll-free

at 877-272-6226, Monday-Friday from 7am-5pm Pacic

Time or e-mail [email protected].

PATIENT NAVIGATION OUTREACH PROGRAM LAUNCHED

The Palette Fund, a foundation that honors the legacy of

Rand Skolnick, who died from pancreatic cancer in 2008,

has graciously partnered with the Pancreatic Cancer Action

Network to fund the Patient Navigation Outreach Program.

We are deeply grateful to The Palette Fund for funding this

important program, said Anitra Talley, Director of the Patient

and Liaison Services (PALS) program. Through their generos-

ity, Rands vision is being realized, and his philanthropic legacy

is honored through collaborative grant-making and programs

that value human rights and education. This program denitely

furthers these goals, as it will positively impact the thousands

of people who must face this disease each year.

The Palette Fund hopes to create a groundswell of con-

sciousness and change to nd new ways to bring Rands

philanthropic legacy and aid to as many people and causes

as possible, as well as to inspire people to join a grassroots

movement to help others in need. In the end, they hope that

one mans death will better the lives of thousands of others.

The pancreatic cancer community will undoubtedly

benet in countless ways because of the generosity and

commitment of The Palette Fund and their vision to support

the Patient Navigation Outreach Program as a tribute to the

memory of Rand, she added.

To nd out more, visit www.thepalettefund.org.

THE PALETTE FUND SUPPORTS INNOVATIVE NEW PROGRAM


10/16


PANCREATIC CANCER STUDY RESULTS PRESENTED ATAMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETINGAt the American Society of Clinical Oncology (ASCO) Annual

Meeting, held in Chicago from June 4 to 8, 2010, investigators

shared results of several clinical trials for the treatment ofpancreatic adenocarcinoma. Summaries of a selection of

these studies appear below.

PHASE III RESULTS

In a Phase III study conducted in France, metastatic

pancreatic cancer patients who were treated with a

chemotherapy regimen called FOLFIRINOX, consisting of

the drugs 5-FU, leucovorin, irinotecan and oxaliplatin, were

compared to patients treated with the current standard of

care, gemcitabine (Gemzar) alone. All 342 patients enrolled

in the study were otherwise healthy and had received no

previous treatment.

Encouragingly, patients treated with the FOLFIRINOX

regimen survived 11.1 months on average, compared to 6.8

months for those treated with gemcitabine. These results

suggest that FOLFIRINOX may be considered for those with

metastatic pancreatic cancer who are healthy enough to

withstand potential side effects. This study reected the rst

positive Phase III clinical trial for such patients since 2005.

Patients treated with FOLFIRINOX experienced worse,

yet manageable, side effects. These side effects included

low white-blood cell and platelet count, vomiting, fatigue,

diarrhea and numbness or pain in the hands and feet.

Another Phase III trial, conducted in Germany, enrolled 281

patients with locally advanced or metastatic pancreatic

cancer. The rst group was treated with gemcitabine plus

erlotinib (Tarceva) followed by capecitabine (Xeloda), a

common treatment regimen. The second, and experimental,

group was treated with capecitabine plus erlotinib, followed

by gemcitabine. In both groups, the patients were initially

treated with the combination therapies and then received the

second-line drug if their cancer progressed.

Study investigators compared the length of time until the

second-line treatment was discontinued in each group.

They sought to determine if this length of time would be

non-inferior in the experimental group. The non-inferiority of

the experimental group was demonstrated and the patients

overall survival was comparable between the arms.

The study did not reveal a new treatment regimen but

showed that investigators may choose to consider building

on capecitabine when developing new rst-line regimens.

PHASE II RESULTS

A Phase II study presented at the meeting compared

gemcitabine alone to two other combinations: a targeted

therapy drug called conatumumab plus gemcitabine,

and another targeted therapy drug called AMG 479 plus

gemcitabine. This study evaluated 125 otherwise healthy

patients with metastatic pancreatic cancer who had not

received prior treatment.

Researchers wanted to learn if either of the new combinations

showed better overall survival than gemcitabine alone. No

signicant differences in overall survival were seen, but

investigators did see a trend towards longer length of time

before the disease began to progress in both combination

arms. While more information is needed to draw any

conclusions about these regimens, the combinations were

well tolerated and warrant further study.

Additionally, a Phase I/II study of Rexin-G, a targeted genetic

drug, was presented. This study looked at the safety and

efcacy of Rexin-G as a treatment for metastatic pancreatic

cancer that progressed after treatment with gemcitabine.

Fifteen patients were given one of three dose-levels of

Rexin-G for four weeks followed by additional treatment if

they did not experience signicant side effects.

Overall, no signicant toxicities were seen and there

appeared to be a correlation between overall survival and the

cumulative amount of Rexin-G administered. This evidence

suggests that Rexin-G may control tumor growth and prolong

survival, so further clinical studies are warranted.

For more information about these studies or treatment

options, or for a personalized clinical trial search, contact

Patient and Liaison Services (PALS) toll-free Monday-

Friday from 7am-5pm, Pacic Time, at 877-272-6226 or

e-mail [email protected].

UPCOMING 2011 PANCREATIC CANCER EDUCATIONAL EVENTS

Go to www.pancan.org for more information and to register.Information about fall educational lectures held nationwide is available as well.

ChicagoApril 15/ Hyatt Regency Chicago

Join us for information presented by leaders in the eld and networking opportunities with otherpatients, survivors, caregivers and family members.

Washington, D.C.March 19/ Renaissance Washington, D.C.

SeattleMay 20/ Sheraton Seattle Hotel


11/16


In April 2005, at the age of 65, I experienced the rst indica-

tion that something was wrong with my health. At that time,

several people approached me at a youth baseball game and

mentioned, You must be playing a lot of golf lately because

youve got a tan. My wife said it was actually yellow, not tan.

An internists exam conrmed I did not have a suntan but

jaundice, and I was referred to a gastroenterologist for tests to

determine the cause. This doctors opinion was that my prob-

lem was caused by one of three things: gallstones, cancer in

the bile duct or pancreatic cancer. Soon, I was sent to a local

hospital for surgery.

Despite the surgeons positive outlook, I had only been in

surgery for an hour when the doctors found that a st-sized

tumor on my pancreas was too large and too close to a major

blood vessel to be removed. So the surgeon inserted a tem-

porary bypass around the tumor, closed me up and said it was

incurable and I had six months to a year to live. They sug-

gested chemotherapy and radiation to extend my life.

During that period of both chemotherapy and radiation

treatments, friends and family convinced me to get a second

opinion from a doctor who specialized in pancreatic cancer.

So I made an appointment at a regional comprehensive cancercenter with a surgeon who specialized in pancreatic surgeries.

However, because of the location of the tumor and my age,

the prospect of surgery remained daunting. I remember the

second surgeon asking me how badly I wanted to live, since

the surgery is difcult and so is the recovery.

During this stressful time, my wife was my biggest sup-

porter. She said we were going to ght this disease to the

last day. When one has that kind of emotional support, that is

half the battle. In January 2006, the tumor had shrunk to one

centimeter and I underwent a successful Whipple procedure.

The doctors said that I was cancer-free.

About six months later, in July of 2006, I was shocked to

learn that the cancer had returned to my liver. Under the care

of a new oncologist, I was prescribed a more aggressive regi-

men of chemotherapy and a targeted drug in pill form called

Tarceva. By January 2007, a CT scan determined the spots

on my liver had disappeared, so I stopped chemotherapy but

stayed on the daily Tarceva pill.

My cancer was no longer visible and my life pretty much

returned to normal. A few months later, however, I experi-

enced yet another reoccurrence of cancer in the bile duct and

I went through another six months of chemotherapy, which I

successfully completed in September 2007.

My experience with pancreatic cancer is a continual jour-

ney. When one goes through something like this, it changes

ones whole perspective on life. I knew the statistics, but Im

proud to be a ve-year survivor. I also credit my faith and my

familys support for helping me to beat those statistics. This

year I will be celebrating my 71st birthday and my wife and

I will celebrate our 48th wedding anniversary. I want to tell

other pancreatic cancer patients never to give up and to live

life to the fullest every day.

A STORY OF HOPE AND INSPIRATIONBy Denny LaVercombe, Helena, Ala.

PATIENT AND LIAISON SERVICES (PALS)Looking for information about pancreatic cancer? PALS offers comprehensive, high-quality information

resources for patients and caregivers facing pancreatic cancer, including information about the dise

treatment options, clinical trials, side effect and symptom management, diet and nutrition, and sup

resources. To learn more or to order a complimentary education packet, contact a PALS Associate.

El programa de PALS esta disponible en espaol.

Patient and Liaison Services (PALS)

Monday - Friday, 7am - 5pm Pacic Time

Toll-free: 877-272-6226 | E-mail: [email protected]

Denny and Jan LaVercombe with their grandchildren, from left,

Chris, Amber, Kailey, Trent and Grant


12/16


CONGRATULATIONS TO OUR VOLUNTEER LEADERSThanks are due to the following volunteers who began new leadership roles from June 1 to August 31, 2010.Betsy Anteau, Event Coordinator, Indianapolis

Terri Bertoli, Community Representative, TucsonKatie Boucher, Education/Outreach Coordinator,

Providence

Elisa Bowling, Education/Outreach Coordinator, AtlantaJohn Bradley, Afliate Coordinator, Boise

Kathryn Brekle, Event Coordinator, Birmingham

Brenda Coleman, Afliate Coordinator, Twin Cities (MN)Heather Costello, Education/Outreach Coordinator,

Columbus

Lisa Carranza-Habib, Community Representative, Jackson

(WY)Erin Corwin, Afliate Coordinator, Cleveland

Amy Cunningham, Education/Outreach Coordinator,

PhiladelphiaWhitney Davidson, Media Representative, Birmingham

Danielle Dietz, Event Coordinator, Los Angeles

Emily Hanson, Media Representative, ColumbusPaige Hawkins, Education and Outreach Coordinator,

Richmond (VA)

Ginnie Jed, Community Representative, Reno-Tahoe

Kira Johns, Education/Outreach Coordinator, ColumbusTeri Larson, Education/Outreach Coordinator, Twin Cities (MN)

Dennis LaVercombe, Advocacy Coordinator, Birmingham

Feme Liaz, Event Coordinator, PhiladelphiaMichelle Lozano, Event Coordinator, Houston

Tara Maloney Wheeler, Afliate Coordinator, Wilmingon (DE)

Suzy Marshall, Community Representative, HonoluluKimberly McFadden, Community Representative,

Anchorage

Justen Meyer, Event Coordinator, St. LouisDaniel Morris, Media Representative, Boise

Diane Pursel, Event Coordinator, Omaha

Kara Rocha, Event Coordinator, Providence

Diane Schooley-Pettis, Education and OutreachCoordinator, Boise

Eric Stark, Event Coordinator, Boise

Wendy Stoneberg, Advocacy Coordinator, BoiseMichael Timmermann, Media Representative, Los Angeles

Kim Trupiano, Media Representative, Providence

Lori Turner, Community Representative, CharlotteMargot Vela, Event Coordinator, Houston

Elaine Wencil, Education and Outreach Coordinator,

Philadelphia

Gibbie Whelehan, Community Representative, Salt Lake CityTeresa Young, Event Coordinator, Cleveland

VOLUNTEERING FOR LEADERSHIPThe Pancreatic Cancer Action Network is grateful for the

support of thousands of volunteers actively participating in

more than 70 afliates around the country. Through suchvolunteer support, more than $6 million (gross) was raised in

FY 2009-'10 through fundraising events that also generated

signicant awareness.

To ensure our volunteers receive the best resources

and support possible, the Volunteer Advisory Council (VAC),

comprising 15 volunteers from afliates around the country,

provides invaluable leadership and insight throughout

the year. We rely on the perspective and guidance of

VAC members when making many decisions affecting our

volunteers, said Mary Jo Kennedy, Director of Community

Outreach.

This year, they were particularly instrumental inshaping our Community Outreach Leadership Training, re-

crafting the volunteer newsletter and Toolbox, revising our

comprehensive event e-blast policy, and developing branding

for our PurpleStride and TEAMHOPE events, she added.

I was thrilled to be invited onto the Volunteer Advisory

Council, Tammy Andries, a Madison volunteer and a

pancreatic cancer survivor, said. I have a background in

media and marketing and hoped I could make it easier for

other afliates to raise the awareness of this disease. What I

like is that we all have a voice in the Pancreatic Cancer ActionNetwork. We can talk with our volunteers and share their

suggestions or concerns and we know we are being heard."

In addition to Tammy, other VAC members include:

Ayme Zemke, Twin Cities Media Representative

Christina Tabarrini, Philadelphia Co-Afliate Coordinator

Debbie Herrero and Nicole Trella, New Jersey Afliate

Co-coordinators

Gael Sandoval, Detroit Afliate Coordinator

Greg Petrosewicz, Austin Afliate Coordinator

Gretchen Guerra, past Denver Afliate CoordinatorJay Stern, Oklahoma Afliate Coordinator

John Cravero, Chicago Afliate Coordinator

Ken Cunzeman, Baltimore Afliate Coordinator

Michelle Monhart, Bay Area Afliate Coordinator

Sandra Martin, Florida, Tampa Bay Afliate Coordinator

Stephanie Pisarski, St. Louis Event Coordinator

Susan Okula, National Capital Area Afliate Coordinator


13/16


CALIFORNIA8th Annual Walk Through the Vineyards, St. Helena,

6/12/2010

3rd Annual Day With the Sacramento Rivercats, 6/20/2010

Awareness Day With the Angels, Anaheim, 7/17/2010

Timothy J. Marsh Fishing For A Cure, San Diego, 7/17/2010

3rd Annual Fundraiser for a Cure in Memory of Bridget

Fisher, Anaheim, 8/1/2010

Awareness Night With the Giants, San Francisco, 7/30/2010

Strikeout Pancreatic Cancer With the OC Flyers, Fullerton,

8/21/2010

Awareness Night With the Dodgers, Los Angeles, 9/3/2010

Awareness Night With the Los Angeles Galaxy, 9/11/2010

PurpleNight Out at Coyote Cantina, Redondo Beach,

9/27/2010

COLORADO

PurpleStride Pikes Peak 2010, Colorado Springs,

7/31/2010

PurpleStride Western Slope 2010, Montrose, 8/21/2010

PurpleStride Golden Gallop 2010, Golden, 9/11/2010

DISTRICT OF COLUMBIA

PurpleStride Washington, D.C. 2010, 6/19/2010

FLORIDA

Awareness Night With the Manatees, Viera, 7/17/2010Art for the Cure, Altamonte Springs, 8/28/2010

PurpleStride Jacksonville 2010, 9/18/2010

IDAHO

Awareness Night with the Boise Hawks, 8/14/2010

PurpleRide Spoke-d'Alene 2010, Spokane to Coeur

d'Alene, 8/28/2010

IOWA

PurpleStride Iowa 2010, West Des Moines, 9/25/2010

LOUISIANA

Corks N Canvas, Baton Rouge, 7/25/2010

Awareness Night With the Zephyrs, Metairie, 7/29/2010

MARYLAND

PurpleSwim Baltimore 2010 In Memory of Bud Beatty,

8/8/2010

PurpleStride Maryland 2010, Cockeysville, 10/10/2010

MASSACHUSETTS

Dough-Raisers Fundraiser at Uno Chicago Grill, Boston,

6/6/2010

Potluck Family Picnic, Pine Banks Park, 8/28/10

MICHIGANPurpleStride Detroit 2010, 9/12/2010

MINNESOTA

Awareness Night With the Twins, 7/17/2010

PurpleRide Twin Cities 2010, 9/19/2010

PurpleStride Rochester 2010, 9/26/2010

MISSOURI

Hospital Hill Run 2010, Kansas City, 6/5/2010

Purple Night Out 2: St. Louis, Rock Hill, 6/23/2010

Awareness Day With the Cardinals, St. Louis, 8/13/2010

NORTH CAROLINA

PurpleBowl Raleigh-Durham 2010, 8/14/2010

NEW JERSEY

Awareness Day With the Somerset Patriots, 7/18/2010

NEW YORK

Awareness Night With the New York Mets, 7/28/2010

PurpleStride Long Island 2010 in Memory of Jimi Lee,

9/26/2010

OHIO

PurpleStride Cleveland 2010, 6/12/2010

Garage Sale, Worthington, 7/17/2010

PurpleStride Central Ohio 2010, Clifton, 9/18/2010

PENNSYLVANIA

Awareness Night With the Pittsburgh Pirates, 6/18/2010

PurpleStride Pittsburgh 2010 "Pick Up The Pace",

8/15/2010

Awareness Night With NEPA Miners Football, 8/14/2010

TENNESSEE

PurpleStride Chattanooga 2010, 10/10/2010

TEXAS

Awareness Night With the Round Rock Express, 7/21/2010

PurpleStride Austin 2010, 9/25/2010

WASHINGTON

Awareness Day With the Seattle Mariners, 8/29/2010

WEST VIRGINIA

Purple Power Night 2010, Charleston, 7/9/2010

WISCONSIN

Night at Tazino's, Oak Creek, 6/9/2010

Awareness Night With the Mallards, Madison, 8/11/2010

PurpleStride Madison 2010, 9/19/2010

EVENTS SUMMARYJUNE SEPTEMBER 2010


14/16


A wonderful way to pay ongoing tribute to your loved one while raisingawareness and funding for the ght against pancreatic cancer.

www.rstgiving.com/keepthememoryalive

KEEP THE MEMORY ALIVE

CORPORATE CHAMPIONS CONTINUE THE FIGHTThe second annual Tempur-

Pedic Hugs Back campaign

launched this month with

the release of a new andvery cuddly cream-colored

teddy bear. The company

is again joining with their

retailers across the country to participate in the well-received

awareness and fundraising initiative.

Thanks to Tempur-Pedic retailers who participated in the rst

campaign last year, the 2009 Hugs Backcampaign generated

essential nancial support for our inaugural Pathway to

Leadership award, a ve-year research grant that was given

to Zeshaan Rasheed, MD, PhD, a leading pancreatic cancer

researcher at Johns Hopkins University, said Pamela Acosta

Marquardt, Founder and Director of Donor and Corporate

Relations. By helping to fund this grant, Tempur-Pedic and

these retailers made an immediate and indelible impression

on research into the disease.

One of our organization's research priorities is to attract

brilliant scientists and help them develop successful careers

in pancreatic cancer research, added Julie Fleshman,

President and CEO. We are very thankful to Tempur-Pedic

and their generous retailers for helping us to further this goal.

The Hugs Back campaign continues to generate tremendous

excitement and hope throughout the pancreatic cancer

community.

Tempur-Pedic is the Pancreatic Cancer Action Networks rst

national corporate sponsor to make a substantial, multi-year

commitment to the ght against the disease.

This year's Hugs Back campaign begins on October

15 and will run throughout the fall while supplies of the

teddy bears last. Volunteers and supporters nationwide are

encouraged to visit their local participating Tempur-Pedic

retailer and give them some hugs back to thank them fortheir support of and commitment to our cause.

For more information about the 2010 Tempur-Pedic Hugs

Backcampaign, visit www.tempurpedichugsback.com .

NHL HOCKEY FIGHTS CANCERNAMED AS CHARITABLE LEAGUE

PARTNER

The National Hockey League (NHL)

and the NHL Players' Association

have named the Pancreatic Cancer

Action Network as a charitable league partner for their

Hockey Fights Cancer Awareness Month during October for

the upcoming 2010-'11 season. In addition, the NHL and

NHL Players' Association will partially fund a pancreatic

cancer research grant through a generous donation to the

organization.

Were thrilled to be working with the NHL to bring much-

needed national attention to this dreadful disease and are very

grateful to both the NHL and NHL Players' Association for

their support and generosity, said Brian Doremus, Director

of Corporate Relations. As part of Hockey Fights Cancer

Awareness Month, the NHL league ofce has also asked NHL

member teams to help Pancreatic Cancer Action Network

volunteer afliates across the country raise awareness and

funds during October.

Hockey Fights Cancer is a component of the NHL's "Biggest

Assist Happens Off the Ice" campaign, the league's long-

standing tradition of addressing important social issues in

North America and worldwide.

Hockey Fights Cancer is a joint initiative by the NHL and

the NHL Players' Association to raise money and awareness

for hockey's most important ght. To date, more than

$11 million has been raised to support national and local

cancer research institutions, children's hospitals, player

charities and various cancer organizations.

To learn more, visit www.nhl.com and click on HockeyFights Cancer.


15/16


On January 22, 1997, my husband, Randy Stein, was diag-

nosed with stage-four, inoperable pancreatic cancer, with

metastases to the spleen and kidneys. At that time, the doc-

tors told us he only had three months to live.

Healthcare professionals, friends, and family tried to help,

but they really didnt have any experience in dealing with the

disease. The Internet only provided dire statistics and we did

not know of any survivors. Ultimately, we found great medical

care, and we dealt with each challenge as it presented itself.

In spite of that frightening news and the lack of information

available back then, Randy lived for more than eight years

following his diagnosis.

Those years were lled with travel and celebrations, and we

appreciated each day because we gained new insight into

the importance of living. During our journey, we met a woman

named Pamela Acosta Marquardt, who had just founded the

Pancreatic Cancer Action Network, and she asked us to get

involved. This opportunity enabled us to help create a sorely

needed resource for information on the disease and to help

support awareness for a cancer that had previously been

ignored.

We joined other patients, caregivers, and activists in this ef-

fort and found great satisfaction in giving back. We raisedmoney through the organizations annual An Evening with the

Stars gala, and traveled to Washington, D.C. to advocate for

more federal funding for research. Randy sat on the board of

directors as the organizations rst treasurer. After his death,

I became a board member to continue to provide hope anddirection to others.

During the most trying time of our life together, the

Pancreatic Cancer Action Network offered us a lifeline for

support, and we were able to connect with hundreds of

others who were in our same situation. Over the years, the

organization grew, and became the national leader in the

ght against the disease.

After Randys death, I wanted to do something meaningful

to keep his memory alive. I really wanted to make a large

donation to the Pancreatic Cancer Action Network becauseit had been such a large part of our lives, but I knew Randy

would want me to take care of myself rst nancially. After

careful consideration, I came up with a plan to meet both of

these goals.

I began donating money to the Pancreatic Cancer Action

Network as my nances allowed and volunteering whenever I

could. Eventually, I decided to donate part of my estate to the

organization. When I was making these preparations, I found

there were many types of other planned giving vehicles, too.

I even found some that could provide income for me for the

rest of my life and support the organization at the same time.Having the Pancreatic Cancer Action Network in my will en-

ables me to always feel connected to the cause while still

being able to go on with my life like Randy would have wanted.

I know that this organization will always be a part of my life,

so I am glad to support it in any way I can. Hopefully, my

contributions will help the Pancreatic Cancer Action Network

to continue fullling its mission until a cure is found.

Find out how easy it is to create a legacy that will touch

many lives for years to come. To learn more, call Pamela

Acosta Marquardt at 877-272-6226 or e-mail her at

[email protected].

REMEMBERING RANDY: A LEGACY OF LOVE

Randy and Judy Stein

CREATE A LEGACY GIFTA legacy gift ensures that your estate will benet countless lives affected by pancreatic canc

A planned gift to the Pancreatic Cancer Action Network is a wonderful way to help us fulll o

important mission. To learn more about creating a bequest, or other planned giving options, plea

contact Pamela Acosta Marquardt at [email protected] or at 877-272-6226.


16/16

MAKE EVERY

AWARENESS COUNJoin us to know it, ght it, end it and

make awareness count all the time. S

our online store for your purple app

accessories, and more.

WWW.PANCAN.ORG/STORE

Non-Prot Org

US Postage

PAID

Torrance, CA

Permit No.473

2141 Rosecrans Ave., Ste 7000, El Segundo, CA 90245

CALENDAR OF EVENTSDATE EVENT NAME CITY, STATE CONTACT

10/17/2010 6th Annual "Time for Hope" Benet Oak Forest, IL Audrey Montalto at [email protected]

10/17/2010 PurpleStride St. Louis 2010 St. Louis, MO Stephanie Pisarski at [email protected]

11/4/2010 4th Annual Night of Hope - Tampa Bay 2010 Tampa, FL Carol Ferguson at [email protected]

11/6/2010 PurpleStride South Florida Davie/Ft. Lauderdale, FL Kimberly Spelman at [email protected]

11/6/2010 PurpleStride Savannah 2010 Tybee Island, GA Shelly Foster at [email protected]

11/6/2010 PurpleStride Philadelphia 2010 Philadelphia, PA Donna Deoria at [email protected]

11/6/2010 PurpleStride San Antonio 2010 San Antonio, TX Jenny Finkbiner at [email protected]

11/6/2010 Jazzed for Hope 2010 Madison, WI Julie Jacobs at [email protected]

11/7/2010 PurpleStride Orlando 2010 Orlando, FL Diane Germ at [email protected]

11/7/2010 PurpleStride Raleigh-Durham 2010 Raleigh, NC Marisa Grant at [email protected]

11/7/2010 PurpleStride Danbury 2010 Danbury, CT Kristen Angell at [email protected]

11/7/2010 PurpleStride New Jersey 2010 Parsippany, NJ Nicole Trella at [email protected]

11/7/2010 PurpleStride Portland 2010 Portland, OR Ariane Chapple at [email protected]

11/7/2010 PurpleStride Puget Sound 2010 Bellevue, WA Chelsea Orvella at [email protected]

11/13/2010 PurpleStride Atlanta 2010 Atlanta, GA Nancy Freedman at [email protected]

11/13/2010 PurpleStride Orange County 2010 Irvine, CA Roberta Luna at [email protected]

11/13/2010 PurpleStride San Diego 2010 Bonita, CA Lily Villaverde at [email protected]

11/14/2010 PurpleStride DFW 2010 Dallas, TX Mary Jo Jennings at [email protected]

12/5/2010 PurpleStride Lake Area 2010 Lake Charles, LA Kristi Remy at [email protected]

TO CONTACT USIf your address is incorrect, or you are receiving duplicate

of this publication, you may submit changes in one of thre

e-mail [email protected]; update the label and mail it

reach/ PanCAN, 2141 Rosecrans Ave., Suite 7000, El Segu

90245; or call 877-272-6226. By giving the code number

pears above your name, your request can be processed

Thank you for helping us to manage our expenses.

outreach oct 2010

Documents